Welcome to our dedicated page for Evoke Pharma news (Ticker: EVOK), a resource for investors and traders seeking the latest updates and insights on Evoke Pharma stock.
Evoke Pharma, Inc. was a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, with emphasis on GIMOTI, a metoclopramide nasal spray for relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Company news has centered on GIMOTI commercialization, specialty pharmacy and GI practice access, FDA Orange Book and USPTO patent developments, product safety information, and periodic operating results.
Evoke became a wholly owned subsidiary of QOL Medical after a completed tender offer and merger, and its common stock ceased trading on Nasdaq. Subsequent company updates reflect that corporate-status transition alongside the historical GIMOTI business.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Evoke Pharma (NASDAQ: EVOK), a specialty pharmaceutical company focusing on gastrointestinal (GI) treatments, has announced the issuance of US patent No. 11,628,150 for its GIMOTI® (metoclopramide) nasal spray. This patent, expiring in 2029, covers specific formulations of metoclopramide. The company intends to list this patent in the FDA Orange Book shortly, enhancing its patent portfolio alongside existing patents in the EU, Japan, Canada, and Mexico. CEO Matt D'Onofrio emphasized the importance of this patent in protecting GIMOTI's proprietary administration route, vital for commercial success. GIMOTI addresses symptoms of diabetic gastroparesis, a serious GI disorder affecting many patients globally. This approval reinforces Evoke's commitment to innovation in the GI space.